[go: up one dir, main page]

HUP0300586A2 - Módosított VIII-as faktor - Google Patents

Módosított VIII-as faktor

Info

Publication number
HUP0300586A2
HUP0300586A2 HU0300586A HUP0300586A HUP0300586A2 HU P0300586 A2 HUP0300586 A2 HU P0300586A2 HU 0300586 A HU0300586 A HU 0300586A HU P0300586 A HUP0300586 A HU P0300586A HU P0300586 A2 HUP0300586 A2 HU P0300586A2
Authority
HU
Hungary
Prior art keywords
factor viii
modified factor
modified
hemophilia
domain
Prior art date
Application number
HU0300586A
Other languages
English (en)
Inventor
John S. Lollar
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of HUP0300586A2 publication Critical patent/HUP0300586A2/hu
Publication of HUP0300586A3 publication Critical patent/HUP0300586A3/hu
Publication of HU227804B1 publication Critical patent/HU227804B1/hu
Priority to HUS1600020C priority Critical patent/HUS1600020I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgya módosított, B-domén nélküli sertés VIII-as faktor,az ezt kódoló DNS, valamint ennek alkalmazása a hemofíliagyógyításában. Ó
HU0300586A 2000-03-10 2001-02-16 Modified factor viii HU227804B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1600020C HUS1600020I1 (hu) 2000-03-10 2016-05-09 Módosított VIII-as faktor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (3)

Publication Number Publication Date
HUP0300586A2 true HUP0300586A2 (hu) 2003-06-28
HUP0300586A3 HUP0300586A3 (en) 2006-11-28
HU227804B1 HU227804B1 (en) 2012-03-28

Family

ID=24085870

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0300586A HU227804B1 (en) 2000-03-10 2001-02-16 Modified factor viii
HUS1600020C HUS1600020I1 (hu) 2000-03-10 2016-05-09 Módosított VIII-as faktor

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1600020C HUS1600020I1 (hu) 2000-03-10 2016-05-09 Módosított VIII-as faktor

Country Status (36)

Country Link
US (3) US6458563B1 (hu)
EP (1) EP1280540B1 (hu)
JP (1) JP4044337B2 (hu)
KR (1) KR100485525B1 (hu)
CN (1) CN1191360C (hu)
AT (1) ATE391512T1 (hu)
AU (2) AU3841601A (hu)
BE (1) BE2016C024I2 (hu)
BR (2) BRPI0109131B8 (hu)
CA (1) CA2400295C (hu)
CY (2) CY1108179T1 (hu)
CZ (1) CZ298250B6 (hu)
DE (1) DE60133541T2 (hu)
DK (1) DK1280540T3 (hu)
EE (1) EE05075B1 (hu)
ES (1) ES2304379T3 (hu)
FR (1) FR16C0016I2 (hu)
HK (1) HK1051004A1 (hu)
HU (2) HU227804B1 (hu)
IL (2) IL151371A0 (hu)
LT (1) LTC1280540I2 (hu)
LU (1) LU93049I2 (hu)
ME (1) ME00601B (hu)
MX (1) MXPA02008798A (hu)
NL (1) NL300808I2 (hu)
NO (2) NO331935B1 (hu)
NZ (1) NZ520799A (hu)
PL (1) PL202936B1 (hu)
PT (1) PT1280540E (hu)
RS (1) RS50364B (hu)
RU (1) RU2285724C2 (hu)
SI (1) SI1280540T1 (hu)
SK (1) SK286205B6 (hu)
UA (1) UA75064C2 (hu)
WO (1) WO2001068109A1 (hu)
ZA (1) ZA200206810B (hu)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
CA2461443C (en) 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7709224B2 (en) * 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
ES2289528T3 (es) * 2003-06-26 2008-02-01 Merck Patent Gmbh Proteinas de trombopoyetina con propiedades mejoradas.
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
SI1750733T1 (sl) * 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
WO2006063031A2 (en) * 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP2009518345A (ja) 2005-12-07 2009-05-07 テフニーシェ ウニヴェルジテート ミュンヘン 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
ES2349024T3 (es) * 2006-04-11 2010-12-21 Csl Behring Gmbh Metodo para aumentar la recuperacion in vivo de polipeptidos terapeuticos.
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
AU2008319183B2 (en) 2007-11-01 2014-09-04 University Of Rochester Recombinant factor VIII having increased stability
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
CA2764872C (en) 2009-06-09 2018-07-24 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
US20130123181A1 (en) * 2009-11-13 2013-05-16 Kathleen Pratt Factor VIII T Cell Epitope Variants Having Reduced Immunogenicity
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US20130216513A1 (en) 2010-07-09 2013-08-22 Biogen Idec Hemophilia Inc. Chimeric Clotting Factors
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
MX347503B (es) * 2010-11-05 2017-04-26 Baxalta Inc Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
AU2012204328A1 (en) * 2011-01-05 2013-07-11 Expression Therapeutics, Llc Method and system for suspension cell culture
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
KR101829603B1 (ko) 2011-07-08 2018-02-19 바이오버라티브 테라퓨틱스 인크. Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
SI2804623T1 (sl) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc. Himerni polipeptidi faktorja VIII in njihove uporabe
PT3453402T (pt) 2012-01-12 2021-10-26 Puget Sound Blood Center Redução da imunogenicidade contra o fator viii em indivíduos sendo submetidos a terapia com o fator viii
CN104487452A (zh) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 因子viii组合物及其制备和使用方法
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
JP6387392B2 (ja) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子ポリペプチド製剤
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
SG10201710616XA (en) 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CA2928314A1 (en) 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
RS63583B1 (sr) 2014-01-10 2022-10-31 Bioverativ Therapeutics Inc Himerni proteini faktora viii i njihova upotreba
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
CA2940127A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
TWI850587B (zh) 2015-11-13 2024-08-01 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
MY190067A (en) 2015-11-13 2022-03-24 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
BR112018015659A2 (pt) 2016-02-01 2018-12-26 Bioverativ Therapeutics Inc genes otimizados do fator viii
CN109790529A (zh) 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
MA46967A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
US11633504B2 (en) 2017-05-09 2023-04-25 Emory University Nucleic acids encoding clotting factor variants and their use
AU2018313921B2 (en) 2017-08-09 2024-12-19 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
KR20200118089A (ko) 2018-02-01 2020-10-14 바이오버라티브 테라퓨틱스 인크. 인자 viii을 발현하는 렌티바이러스 벡터의 용도
EP3773517A1 (en) 2018-04-04 2021-02-17 Sigilon Therapeutics, Inc. Implantable particles and related methods
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
AU2019306194A1 (en) 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
WO2020257586A2 (en) 2019-06-20 2020-12-24 Baxalta Incorporated Method of treatment with viral-based gene therapy
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
WO2022212162A1 (en) * 2021-03-31 2022-10-06 Haemonetics Corporation Hemostasis measurement device quality control formulations
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AR126846A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Genes del factor viii optimizados
JP2024537797A (ja) 2021-09-30 2024-10-16 バイオベラティブ セラピューティクス インコーポレイテッド 低下した免疫原性を有する第ｖｉｉｉ因子ポリペプチドをコードする核酸
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ES8801674A1 (es) * 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
HUP0301179A3 (en) * 2000-09-19 2006-11-28 Univ Emory Modified factor viii
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
PL202936B1 (pl) 2009-08-31
CA2400295C (en) 2012-01-10
YU68002A (sh) 2005-11-28
US6458563B1 (en) 2002-10-01
SK14392002A3 (sk) 2003-06-03
ES2304379T3 (es) 2008-10-16
CY2016011I1 (el) 2016-10-05
RU2002124123A (ru) 2004-03-27
SK286205B6 (sk) 2008-05-06
NO20024296L (no) 2002-11-08
EP1280540A1 (en) 2003-02-05
FR16C0016I1 (hu) 2016-04-29
NO2016007I2 (no) 2016-05-10
WO2001068109A1 (en) 2001-09-20
UA75064C2 (en) 2006-03-15
CZ20023346A3 (cs) 2003-01-15
NL300808I1 (hu) 2016-05-18
MEP8209A (en) 2011-12-20
EE200200510A (et) 2004-02-16
HUS1600020I1 (hu) 2016-06-28
IL151371A0 (en) 2003-04-10
JP2003526358A (ja) 2003-09-09
PT1280540E (pt) 2008-06-09
US7012132B2 (en) 2006-03-14
BRPI0109131B1 (pt) 2020-08-25
BR0109131A (pt) 2004-12-07
CY1108179T1 (el) 2014-02-12
DE60133541D1 (de) 2008-05-21
KR100485525B1 (ko) 2005-04-28
AU3841601A (en) 2001-09-24
PL359672A1 (en) 2004-09-06
LTC1280540I2 (lt) 2020-05-25
US20030068785A1 (en) 2003-04-10
US20050079584A1 (en) 2005-04-14
AU2001238416B2 (en) 2004-09-02
CY2016011I2 (el) 2016-10-05
ME00601B (me) 2011-12-20
EP1280540B1 (en) 2008-04-09
RS50364B (sr) 2009-11-10
US7122634B2 (en) 2006-10-17
NZ520799A (en) 2004-06-25
ATE391512T1 (de) 2008-04-15
NO331935B1 (no) 2012-05-07
BRPI0109131B8 (pt) 2021-07-06
LU93049I2 (fr) 2016-06-27
BR122013026957A8 (pt) 2017-02-21
JP4044337B2 (ja) 2008-02-06
NL300808I2 (nl) 2020-12-21
BE2016C024I2 (hu) 2020-01-30
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
DK1280540T3 (da) 2008-07-14
EP1280540A4 (en) 2004-11-03
DE60133541T2 (de) 2009-05-07
KR20020081426A (ko) 2002-10-26
IL151371A (en) 2010-12-30
FR16C0016I2 (fr) 2018-11-02
SI1280540T1 (sl) 2008-08-31
BR122013026957A2 (hu) 2004-12-07
CN1191360C (zh) 2005-03-02
HUP0300586A3 (en) 2006-11-28
NO2016007I1 (no) 2016-05-10
HK1051004A1 (en) 2003-07-18
CZ298250B6 (cs) 2007-08-01
CN1416348A (zh) 2003-05-07
ZA200206810B (en) 2003-11-26
CA2400295A1 (en) 2001-09-20
MXPA02008798A (es) 2003-04-25
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
HUP0300586A2 (hu) Módosított VIII-as faktor
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
DE60041782D1 (de) Bioaktiver und osteoporotischer knochenzement
DE60000992D1 (de) Desinfizierende zusammensetzung auf basis von h2o2, säuren und metallionen
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
HUP0401190A3 (en) Treatment of nail infections using no generating compositions
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
AU144678S (en) Bottle
NO20015785D0 (no) I dets vesentlige oljefrie cyklosporinsammensetninger
DE60120712D1 (en) Kallikrein gen
DE60027326D1 (de) Maca und geweih zur steigerung des testosteronspiegels
MY126868A (en) Suspension comprising oxcarbazepine
DK1238065T3 (da) Faktor X-analog med forbedret evne til aktivering
DE60008353D1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
TR200002939T2 (tr) Paroksetin maleat
BR0210252A (pt) Peptìdeos biologicamente ativos
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner
ITBO20010738A0 (it) Elemento di supporto e rinforzo per protesi dentali o ricostruzioni coronali
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
AU147160S (en) Dental floss container
DE60110503D1 (de) Immunostimulierende Zusammensetzung enthaltend Peptid und Hyaluronsäure
ES1046325Y (es) Implante dental.

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: SUSOCTOCOG; REGISTRATION NO/DATE: EU/1/15/1035 20151113

Spc suppl protection certif: S1600020

Filing date: 20160509

Expiry date: 20210216

FG4S Grant of supplementary protection certificate

Spc suppl protection certif: S1600020

Filing date: 20160509

Expiry date: 20210216

Extension date: 20260216